Spectrum Pharmaceuticals Inc, (Spectrum), formerly NeoTherapeutics, Inc., is a biotechnology company. It carries out the acquisition, development, and commercialization of a pipeline of late-stage clinical and commercial products with particular focus on hematology and oncology. The company has six marketed drugs, namely, Fusilev (levoleucovorin); Folotyn (pralatrexate injection); Zevalin (ibritumomab tiuxetan); Marqibo (vincristine liposomal), Beleodaq (belinostat) and Evomela (Captisol-enabled Melphalan). It also has two drugs in late stage development, namely, apaziquone and SPI-2012. Spectrum in-licenses and enters into co-development partnerships to develop promising products. The company markets its products through direct sales force in the US and through distributors in Europe. Spectrum is headquartered in Henderson, Nevada, the US. This comprehensive SWOT profile of Spectrum Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations.